Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jacob Sands
Dana-Farber - Harvard Cancer Center LAO
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
24 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Los Angeles County-Usc Medical Center
Los Angeles, California, United States
- Usc / Norris Comprehensive Cancer Center
Los Angeles, California, United States
- Keck Medical Center of Usc Pasadena
Pasadena, California, United States
- Mayo Clinic in Florida
Jacksonville, Florida, United States
- Moffitt Cancer Center
Tampa, Florida, United States
- Emory University Hospital Midtown
Atlanta, Georgia, United States
- Emory University Hospital/winship Cancer Institute
Atlanta, Georgia, United States
- University of Kentucky/markey Cancer Center
Lexington, Kentucky, United States
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
- Brigham and Women'S Hospital
Boston, Massachusetts, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
- Mayo Clinic
Rochester, Minnesota, United States
- Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri, United States
- Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, United States
- Siteman Cancer Center at Christian Hospital
St Louis, Missouri, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Laura and Isaac Perlmutter Cancer Center at Nyu Langone
New York, New York, United States
- Case Western Reserve University
Cleveland, Ohio, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
- University of Pittsburgh Cancer Institute (upci)
Pittsburgh, Pennsylvania, United States
- University of Virginia Cancer Center
Charlottesville, Virginia, United States
- Virginia Commonwealth University/massey Cancer Center
Richmond, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Mar 2018
- Primary completion
- 17 Mar 2020
- Completion
- 17 Mar 2020
- Last update posted
- 17 Oct 2023
- Registered enrollment
- 9
- Registry id
- NCT02899728
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.